RAPPORT THERAPEUTICS INC

Rapport Therapeutics drops 2.26% to $25.93 as market pressure hits its 200‑day MA, but its pipeline, cost cuts, and capital plans hint at a potential rebound.

Rapport Therapeutics (RAPP) sees a 14.7% dip yet insiders buy, hinting confidence. Explore its 200‑day SMA break, market cap, and clinical outlook.

Rapport Therapeutics’ stock drops 14.7% amid weak fundamentals, little insider buying, and a steep technical slide below its 200‑day SMA.

Rapport Therapeutics (RAPP) hits a 2.69% rise, trading near $25 with a $1.4B market cap; see how peers and key indicators shape its outlook.